Pathogenic mechanisms of immune checkpoint inhibitor (ICI)-associated retinal and choroidal adverse reactions.

IF 4.1 1区 医学 Q1 OPHTHALMOLOGY American Journal of Ophthalmology Pub Date : 2025-01-02 DOI:10.1016/j.ajo.2024.12.028
Rachana Haliyur, Susan G Elner, Therese Sassalos, Shilpa Kodati, Mark W Johnson
{"title":"Pathogenic mechanisms of immune checkpoint inhibitor (ICI)-associated retinal and choroidal adverse reactions.","authors":"Rachana Haliyur, Susan G Elner, Therese Sassalos, Shilpa Kodati, Mark W Johnson","doi":"10.1016/j.ajo.2024.12.028","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To summarize and categorize postulated mechanisms of immune checkpoint inhibitor (ICI)-mediated retinal and choroidal inflammation and discuss resulting implications for evaluation and management of these adverse reactions.</p><p><strong>Design: </strong>Targeted literature review with interpretation and perspective Methods: We performed a review of selected literature describing immune-mediated retinal and choroidal adverse reactions associated with ICI therapy, synthesizing and categorizing the likely underlying pathogenic mechanisms. Based on these mechanistic categories, we provide perspective on a rational approach to the evaluation of patients with ICI-associated inflammatory disorders of the retina and choroid.</p><p><strong>Results: </strong>ICI-induced posterior segment adverse reactions can be categorized into three major mechanisms of unintended, targeted inflammation that share similarities to immunotherapy-related adverse events (irAEs) seen in other organ systems. In Type 1 reactions, T cell activation by ICIs can result in cross-reactivity of anti-tumor T cells with ocular tissues (Type 1a) or expansion of eye-specific T cells in predisposed individuals (Type 1b), leading to ocular inflammation that mimics known uveitic conditions. In Type 2 reactions, non-specific ocular or systemic inflammation exacerbated by ICI use can cause retinal vasculitis through a \"bystander\" mechanism, potentially resulting in vision-threatening vascular occlusions. Finally, in Type 3 reactions, ICI use can prompt autoantibody-mediated inflammation and/or exacerbation of paraneoplastic processes likely related to T cell driven expansion of B cell populations.</p><p><strong>Conclusions: </strong>Although relatively uncommon, posterior segment inflammatory disorders associated with systemic ICI therapy may be vision-threatening if not identified and treated appropriately. We propose that the pathogenic mechanisms underlying these chorioretinopathies falls into three major categories involving inadvertent T cell mediated inflammation. Visual prognosis with appropriate treatment is generally favorable, but some reactions, such as longstanding exudative retinal detachments and ICI-induced occlusive retinal vasculitis, can result in permanent visual defects.</p>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajo.2024.12.028","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To summarize and categorize postulated mechanisms of immune checkpoint inhibitor (ICI)-mediated retinal and choroidal inflammation and discuss resulting implications for evaluation and management of these adverse reactions.

Design: Targeted literature review with interpretation and perspective Methods: We performed a review of selected literature describing immune-mediated retinal and choroidal adverse reactions associated with ICI therapy, synthesizing and categorizing the likely underlying pathogenic mechanisms. Based on these mechanistic categories, we provide perspective on a rational approach to the evaluation of patients with ICI-associated inflammatory disorders of the retina and choroid.

Results: ICI-induced posterior segment adverse reactions can be categorized into three major mechanisms of unintended, targeted inflammation that share similarities to immunotherapy-related adverse events (irAEs) seen in other organ systems. In Type 1 reactions, T cell activation by ICIs can result in cross-reactivity of anti-tumor T cells with ocular tissues (Type 1a) or expansion of eye-specific T cells in predisposed individuals (Type 1b), leading to ocular inflammation that mimics known uveitic conditions. In Type 2 reactions, non-specific ocular or systemic inflammation exacerbated by ICI use can cause retinal vasculitis through a "bystander" mechanism, potentially resulting in vision-threatening vascular occlusions. Finally, in Type 3 reactions, ICI use can prompt autoantibody-mediated inflammation and/or exacerbation of paraneoplastic processes likely related to T cell driven expansion of B cell populations.

Conclusions: Although relatively uncommon, posterior segment inflammatory disorders associated with systemic ICI therapy may be vision-threatening if not identified and treated appropriately. We propose that the pathogenic mechanisms underlying these chorioretinopathies falls into three major categories involving inadvertent T cell mediated inflammation. Visual prognosis with appropriate treatment is generally favorable, but some reactions, such as longstanding exudative retinal detachments and ICI-induced occlusive retinal vasculitis, can result in permanent visual defects.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
免疫检查点抑制剂(ICI)相关视网膜和脉络膜不良反应的致病机制。
目的:总结和分类免疫检查点抑制剂(ICI)介导的视网膜和脉络膜炎症的假设机制,并讨论对这些不良反应的评估和管理的影响。设计:有针对性的文献综述,具有解释和视角。方法:我们对选择性文献进行综述,这些文献描述了与ICI治疗相关的免疫介导的视网膜和脉络膜不良反应,综合并分类了可能的潜在致病机制。基于这些机制分类,我们为ici相关的视网膜和脉络膜炎症性疾病患者的评估提供了合理的方法。结果:ici诱导的后段不良反应可分为三种主要的非预期的靶向炎症机制,它们与其他器官系统中观察到的免疫治疗相关不良事件(irAEs)有相似之处。在1型反应中,ICIs激活T细胞可导致抗肿瘤T细胞与眼组织(1a型)的交叉反应,或易感个体中眼睛特异性T细胞的扩增(1b型),导致模仿已知葡萄膜状况的眼部炎症。在2型反应中,使用ICI加剧的非特异性眼部或全身炎症可通过“旁观者”机制引起视网膜血管炎,可能导致威胁视力的血管闭塞。最后,在3型反应中,使用ICI可促进自身抗体介导的炎症和/或可能与T细胞驱动的B细胞群扩增相关的副肿瘤过程的加剧。结论:虽然相对罕见,但如果不及时发现和适当治疗,与全身ICI治疗相关的后段炎性疾病可能会对视力造成威胁。我们提出这些脉络膜视网膜病变的致病机制分为三大类,涉及无意的T细胞介导的炎症。通过适当的治疗,视力预后通常是良好的,但一些反应,如长期渗出性视网膜脱离和ici诱导的闭塞性视网膜血管炎,可导致永久性视力缺陷。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.20
自引率
7.10%
发文量
406
审稿时长
36 days
期刊介绍: The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented online at www.AJO.com and on ScienceDirect. The American Journal of Ophthalmology publishes Full-Length Articles, Perspectives, Editorials, Correspondences, Books Reports and Announcements. Brief Reports and Case Reports are no longer published. We recommend submitting Brief Reports and Case Reports to our companion publication, the American Journal of Ophthalmology Case Reports. Manuscripts are accepted with the understanding that they have not been and will not be published elsewhere substantially in any format, and that there are no ethical problems with the content or data collection. Authors may be requested to produce the data upon which the manuscript is based and to answer expeditiously any questions about the manuscript or its authors.
期刊最新文献
Comment on: Association Between Glucagon-Like Peptide 1 Receptor Agonists Exposure and Intraocular Pressure Change. Response to: "Comment on: Association between Glucagon-Like Peptide 1 Receptor Agonists Exposure and Intraocular Pressure Change". Comment on Ophthalmic Immune-Related Adverse Events and Association With Survival: Results From a Real-World Database. Reply to Comment on Ophthalmic Immune-Related Adverse Events and Association With Survival: Results From a Real-World Database. Clinical outcomes in peripheral ulcerative keratitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1